e-learning
resources
London 2016
Tuesday, 06.09.2016
Preclinical pharmacology: drug targets and mechanisms of action
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Evaluation of indacaterol and glycopyrronium as inhalation powder on systemic inflammatory and oxidative stress parameters in severe COPD
Balakrishnan Menon (Delhi, India), Balakrishnan Menon, Charanjeet Kaur, Harsh Vardhan, Mohammad Yusuf Dar
Source:
International Congress 2016 – Preclinical pharmacology: drug targets and mechanisms of action
Session:
Preclinical pharmacology: drug targets and mechanisms of action
Session type:
Thematic Poster
Number:
4098
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Balakrishnan Menon (Delhi, India), Balakrishnan Menon, Charanjeet Kaur, Harsh Vardhan, Mohammad Yusuf Dar. Evaluation of indacaterol and glycopyrronium as inhalation powder on systemic inflammatory and oxidative stress parameters in severe COPD. Eur Respir J 2016; 48: Suppl. 60, 4098
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Panel discussion on ERS Statement – A core outcome set for clinical trials evaluating the management of COPD exacerbations
ERS statement: a core outcome set for clinical trials evaluating the management of COPD exacerbations
Evidence-based eHealth for COPD
Related content which might interest you:
Efficacy of tiotropium and indacaterol alone or the combination on dynamic lung hyperinflation and exercise tolerance in COPD
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
The combination therapy with inhaled tiotropium bromide and indacaterol in COPD improves the peripheral airway function in static and dynamic status
Source: International Congress 2014 – Asthma and COPD management
Year: 2014
The impact of stepwise withdrawal of inhaled corticosteroids on lung function in COPD patients receiving dual bronchodilation: WISDOM study
Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments
Year: 2014
Airway inflammation in COPD after long-term withdrawal of inhaled corticosteroids
Source: International Congress 2016 – New findings in mucosal immunology
Year: 2016
Oxidative stress and systemic inflammation in different COPD phenotypes
Source: International Congress 2014 – Monitoring COPD with different biomarkers
Year: 2014
Positive outcomes of 900 mg daily erdosteine in acute exacerbation of COPD
Source: Annual Congress 2013 –New clinical trials of asthma and COPD drugs
Year: 2013
The inflammatory response to high doses of terbutaline during an acute exercise bout in patients with severe COPD
Source: Annual Congress 2013 –Respiratory and cardiovascular abnormalities in COPD: the role of exercise, nutritional status and inflammation
Year: 2013
Adiponectin is associated with dynamic hyperinflation and a favourable response to inhaled glucocorticoids in patients with COPD
Source: International Congress 2014 – Translational studies in COPD
Year: 2014
Pulmonary response to salbutamol inhalation using dynamic OE-MRI in patients with asthma
Source: Annual Congress 2013 –The different modalities for current imaging and for future issues
Year: 2013
Features of systemic inflammation in patients with stable COPD
Source: International Congress 2014 – COPD: points to ponder
Year: 2014
Endothelial dysfunction and systemic inflammation in different COPD phenotypes
Source: International Congress 2014 – COPD physiopathology
Year: 2014
Rosuvastatin effects on systemic inflammation, oxidative stress and antioxidants in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – COPD diagnosis and management
Year: 2016
Effect of tiotropium compared to salmetrol on dynamic hyperinflation in patients with chronic obstructive pulmonary disease
Source: International Congress 2016 – Novel avenues in the treatment of COPD I
Year: 2016
Hemodynamic effects of inhaled fenoterol and ipratropium in patients with obstructive pulmonary diseases
Source: International Congress 2014 – Monitoring airway diseases with lung function tests
Year: 2014
A prospective study of the effect of carbocysteine lysine salt on COPD exacerbations with or without inhaled steroids
Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases
Year: 2014
The role of nebulised budesonide in the treatment of exacerbations of COPD
Source: Eur Respir J 2007; 29: 660-667
Year: 2007
Endothelial dysfunction and systemic inflammation during acute exacerbations of COPD
Source: International Congress 2016 – Biomarkers and phenotypes of COPD
Year: 2016
Pharmacological activities of roflumilast N-oxide, dexamethasone and formoterol in human neutrophils from healthy non-smokers and COPD patients
Source: International Congress 2014 – Novel approaches and evidence for drug development in respiratory diseases
Year: 2014
Monitoring oxidative stress during recovery from COPD exacerbations: Comparison of airway and systemic malondialdehyde levels
Source: International Congress 2016 – Airway biomarkers
Year: 2016
Tiotropium effects on airway inflammatory events in the cat as an animal model for acute cigarette smoke-induced lung inflammation
Source: International Congress 2014 – Animal models: asthma, COPD and beyond
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept